Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.68 |
| ▸ | PPARG | P37231 | 7/20 | 0.68 |
| ▸ | PPARD | Q03181 | 7/20 | 0.68 |
| ▸ | PPARA | Q07869 | 7/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | TLR2 | O60603 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | FABP4 | P15090 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820782 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL6156790 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| Stearic Acid SCHEMBL2345342 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| Octanoic Acid SCHEMBL20394217 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| Behenic Acid SCHEMBL20658937 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| Palmitic Acid SCHEMBL20876307 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| Myristic Acid SCHEMBL25309729 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| Decanoic Acid SCHEMBL8937980 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL3146458 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL9580633 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-4326330-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | Novartis AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| CN-117202936-A | Glucagon-like peptide compounds | 诺华股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| WO-2022224164-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
| WO-2015200080-A1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200078-A1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015179415-A1 | METHODS OF TREATING ANOREXIA | NOVARTIS AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| WO-2015013168-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| WO-2015013169-A2 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2015-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | FFAR4 18/4885FFAR1 10/4885GPR84 236/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | FFAR4 1857/4885FFAR1 2823/4885GPR84 1136/4885 |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | FFAR4 626/4885FFAR1 515/4885GPR84 614/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | FFAR4 3082/4885FFAR1 3086/4885GPR84 439/4885 |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | FFAR4 18/4885FFAR1 10/4885GPR84 236/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | FFAR4 19/4885FFAR1 10/4885GPR84 278/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | FFAR4 3404/4885FFAR1 3521/4885GPR84 589/4885 |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | FFAR4 906/4885FFAR1 498/4885GPR84 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.